Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now early-phase tilt small index

Autoimmune Disease: early-phase trial registry

7 of 11 indexed Autoimmune Disease trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

11 US clinical trials · 7 currently recruiting · #1,577 of 28,707 conditions by registered trial count

Autoimmune Disease: 11 US clinical trials tracked, 7 recruiting.

Autoimmune Disease is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Fred Hutchinson Cancer Center, running 2 of these trials.

Enrollment posture brief

Registry condition autoimmune-disease

OPEN 7 | RECR 64% | LATE 0 | EARLY 5 | RANK #1577 | SPON 2

Nearest open-share peer: Advanced Melanoma (64% recruiting · 22 trials)

Acute Pancreatitis81.8%Autoimmune Disease (this)64%Acute Stroke45.5%Acquired Brain Injury36.4%Acute Lung Injury9.1%
Open-enrollment share among volume-matched conditions near Autoimmune Disease

Autoimmune Disease lists 7 open slots (64% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Autoimmune Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Autoimmune Disease is recruiting above its size-band peers.

    7 of 11 indexed trials (63.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Autoimmune Disease research.

    Fred Hutchinson Cancer Center accounts for 2 of 11 trials (18.2%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Typical Autoimmune Disease enrolment sits around 130 participants.

    Median target enrolment is 130 among the 11 trials that report a genuine target (sentinel values excluded). 4 of those (36.4%) plan for fewer than 100 participants.

  4. Autoimmune Disease splits between interventional and observational designs.

    5 interventional and 6 observational studies make up this index (45.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 23

Open and recent trials

11 total, page 1 of 1

RECRUITING 1,500 participants

Autoimmune and Autoinflammatory Genetics Study

NYU Langone Health

NCT06004349

RECRUITING 1,200 participants

The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

University of Chicago

NCT01280825

RECRUITING 900 participants

Natural History of Bronchiectasis

National Heart, Lung, and Blood Institute (NHLBI)

NCT00943514

RECRUITING Phase 1 300 participants

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

National Cancer Institute (NCI)

NCT03816345

RECRUITING 125 participants

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

M.D. Anderson Cancer Center

NCT04751396

RECRUITING Phase 2 60 participants

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

Fred Hutchinson Cancer Center

NCT06817889

RECRUITING Phase 2 30 participants

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00977977

ACTIVE NOT RECRUITING Phase 2 53 participants

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

Fred Hutchinson Cancer Center

NCT00716066

COMPLETED 10,805 participants

Continuation of Follow-up of DES-Exposed Cohorts

National Cancer Institute (NCI)

NCT00340600

COMPLETED 130 participants

Identify Clinical Conditions That Increase Circulating DNA Levels

University of Florida

NCT01815996

COMPLETED Phase 1 8 participants

Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00013689

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3

Named interventions

Most-linked intervention names on Autoimmune Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Survey Administration Other
2 trials
Biospecimen Collection Procedure
2 trials
One time blood draw to look at patient's DNA Other
1 trials
Fansidar (pyrimethamine and sulfadoxine) Drug
1 trials
Oral Cyclosporine Drug
1 trials
Rituximab Infusion Drug
1 trials
Nasal Swab Procedure
1 trials
Remdesivir Drug
1 trials

US sites by state

Facility locations filed on Autoimmune Disease trials. A trial with sites in several states counts in each.

Maryland 3 trials
Washington 2 trials
Texas 2 trials
Illinois 2 trials
California 2 trials
New York 1 trials
Massachusetts 1 trials
Kansas 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Autoimmune Disease page

11 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Autoimmune Disease condition card totals 11 registered trials; most-linked intervention Survey Administration; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.